Sector News

Want international growth? Africa’s set to double pharma sales in 5 years

June 17, 2015
Life sciences
Pharma growth in China may be slowing and Europe stalling, but there’s one area where drugmakers might actually achieve some big growth, according to McKinsey & Co. That’s Africa, a mere $4.7 billion market in 2003 and $20.8 billion a decade later.
 
And now? McKinsey numbers put the African drug market at $52 billion by 2020–and as high as $65 billion on the optimistic end of things. Even at the low end of their projections–$40 billion–that’s twice the level of 2013 sales.
 
The growth drivers are familiar–and similar to other emerging markets. Africa is growing increasingly urbanized, which means better infrastructure and greater household purchasing power. Healthcare capacity is also growing, with 70,000 new hospital beds and 76,000 new doctors and nurses added between 2005 and 2012. And healthcare systems are broadening their reach beyond typical healthcare facilities. Plus, governments are increasingly supportive of the pharma business, with new rules encouraging local drug manufacturing and anticounterfeiting measures.
 
In a sense, Africa is where other emerging markets were a few years ago–and that means bigger growth potential over the next decade. “In a world of slowing and stagnating markets, Africa represents perhaps the last geographic frontier where genuinely high growth is still achievable,” the McKinsey consultants conclude.
 
The challenges of emerging markets growth apply in Africa, of course, with on-the-ground knowledge and relationships key to success. One focus for Africa-ambitious pharmas should be recruiting local sales-and-marketing talent and developing strong local managers, the report states. Also important are business partners in manufacturing and distribution–not to mention partnerships with local governments.
 
Drugmakers might want to focus on expanding city by city rather than country by country in Africa, with 37% of African consumers concentrated in just 30 cities. And it’s smart to set up capital-intensive operations in countries where governments are most stable and business regulations best developed. Outsourcing supply chains can be a good move, too, McKinsey says. And with transportation a widespread barrier, local partners are the best sources for ID’ing the most efficient ways to get products to the right place.
 
“As ever, the key to success lies in understanding individual markets in granular detail,” the report states. “Early movers with the right approach should be able to capture competitive advantage. … Now is the time for drug companies to decide whether they want to be part of that growth and, more important, play an active role in improving public health.”
 
By Tracy Staton
 

comments closed

Related News

November 28, 2021

Founder-led biotech is making space for ideas—and diverse leaders—where it didn’t exist before

Life sciences

Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.

November 28, 2021

Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine: analyst

Life sciences

Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.

November 28, 2021

GlaxoSmithKline takes aim at sick pay access inequities with microgrant program and new campaign

Life sciences

In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.

Send this to a friend